Favorable response to subcutaneous administration of infliximab in rats with experimental colitis

Table 1 Comparison of histological lesions in treated and untreated groups of animals (mean±SD)

Group	Active ulcers and erosions	P value	Reparative lesions	P value
1 (Infliximab 5, n = 6)	0.07±0.12	0.30	0.38±0.12	0.0001
2 (Infliximab 10, n = 6)	3.77±5.07	0.42	0.80±0.14	0.0001
3 (Infliximab 15, n = 6)	25.02±38.90	1.00	1.00±0.47	0.0001
4 (Untreated, n = 12)	25.00±38.91		15.00±5.48

Table 2 Percentage of bowel area without active inflammation in treated and untreated groups of animals (mean±SD)

Group	Percentage of mucosa without active inflammation	P value
1 (Infliximab 5)	99.55±0.19	0.049
2 (Infliximab 10)	95.43±5.15	0.088
3 (Infliximab 15)	73.98±39.29	0.705
4 (Untreated)	60.00±37.18

Table 3 Tissue TNF-α levels in treated and untreated groups of animals (mean±SD)

Group	Tissue TNF-α (pg/mL)	P value
1 (Infliximab 5)	0.47±0.44	<0.0001
2 (Infliximab 10)	1.09±0.86	<0.0001
3 (Infliximab 15)	0.43±0.31	<0.0001
4 (Untreated)	18.73±10.53
5 (Healthy animals)	0.00+/–0.0

Table 4 Mean value of tissue malondialdehyde in treated and untreated groups of animals (mean±SD)

Group	Serum malondialdehyde (μmol/l)	P value
1 (Infliximab 5)	1.85±0.20	0.017
2 (Infliximab 10)	1.84±0.37	0.011
3 (Infliximab 15)	2.29±0.56	0.272
4 (Untreated)	2.73±0.46
5 (Healthy animals)	1.11+/–0.19